Dimension Therapeutics Completes Strategic Review

Dimension Therapeutics provided on Tuesday a corporate update following completion of a strategic review. The company said it expects to realize savings in operating expenses, including personnel costs, as a result of streamlining headcount by approximately 25% by the end of 2017. As part of its priority initiatives for 2017/2018, the company said that it has ongoing nonclinical activities supporting selection of a candidate for Wilson disease (DTX701) in H1 of 2018. It also anticipates an IND filing early 2018 in collaboration with Bayer for the treatment of moderate/severe to severe hemophilia A, and expects initial data from a trial of DTX201 for that disease in 2018.

As of March 31, Dimension had $59.1 million in cash, cash equivalents and marketable securities, which, along with reimbursements and $15 million of potential milestones to be received in connection with its collaboration agreement with Bayer, is expected to enable Dimension to fund operations to the end of 2018. Without the milestones, the company says it would only be able to fund operations to mid-2018.

By Caroline Williams